On October 23rd, 2014, we updated our
By continuing to use LinkedIn’s SlideShare service, you agree to the revised terms, so please take a few minutes to review them.
You can also request for sample page of abovemention reports on email@example.com
Pages : 41PDF - $ 2000 | Site Licence - $ 4000 $ | Enterprise License - $6000 |20% Off on above 1000$ Reports25% off on purchase of 2 reports and 30% on purchase of3 or more reports.Discount till 31st Dec. 2012.
Summary Global Markets Direct’s, Pheochromocytoma - Pipeline Review, H2 2012,provides an overview of the indication’s therapeutic pipeline. This reportprovides information on the therapeutic development forPheochromocytoma, complete with latest updates, and special features onlate-stage and discontinued projects. It also reviews key players involved inthe therapeutic development for Pheochromocytoma. Pheochromocytoma -Pipeline Review, Half Year is built using data and information sourced fromGlobal Markets Direct’s proprietary databases, Company/Universitywebsites, SEC filings, investor presentations and featured press releasesfrom company/university sites and industry-specific third party sources,put together by Global Markets Direct’s team.Note*: Certain sections in the report may be removed or altered based onthe availability and relevance of data for the indicated disease.
Scope - A snapshot of the global therapeutic scenario for Pheochromocytoma. - A review of the Pheochromocytoma products under development bycompanies and universities/research institutes based on information derivedfrom company and industry-specific sources. - Coverage of products based on various stages of development ranging fromdiscovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combinedtherapeutics.Reasons to buy- Identify and understand important and diverse types of therapeutics underdevelopment for Pheochromocytoma.- Identify emerging players with potentially strong product portfolio and designeffective counter-strategies to gain competitive advantage.- Plan mergers and acquisitions effectively by identifying players of the mostpromising pipeline.
Table of Contents : List of Tables 4List of Figures 4Introduction 5Global Markets Direct Report Coverage 5Pheochromocytoma Overview 6Therapeutics Development 7An Overview of Pipeline Products for Pheochromocytoma 7Pheochromocytoma Therapeutics under Development by Companies 9Pheochromocytoma Therapeutics under Investigation byUniversities/Institutes 10Mid Clinical Stage Products 12Comparative Analysis 12Early Clinical Stage Products 13Comparative Analysis 13Pheochromocytoma Therapeutics – Products under Development byCompanies 14Pheochromocytoma Therapeutics – Products under Investigation byUniversities/Institutes 15………………
Please follow link if you want More RelatedReports :Pipeline Review, H2 2012http://www.aarkstore.com/search/viewresults.asp?search=PipelineReview, H2 2012&PubId=&pagenum=1
For More details about above & otherReports plz contact :LavanyaAarkstore.comContact: Marketing team Mob.No.918149852585Email: firstname.lastname@example.org ,email@example.comURL: http://www.aarkstore.comhttp://in.linkedin.com/in/aarkstorehttp://www.facebook.com/aarkstore